The New Brunswick, New Jersey-based Johnson & Johnson (NYSE:JNJ), the world’s top seller of health-care products, reported that it would set aside $600 million in the Q2 to boost its reserves for potential settlements of civil lawsuits charging it unlawfully marketed medicines comprising the anti-psychotic treatments Risperdal and Invega.
The drug maker Johnson & Johnson reported in its January earnings report that J&J established reserves of $1.7 billion in 2011 for court case settlements.
An Arkansas state judge in April prepared J&J to pay over $1.1 billion for illegally marketing and misinforming doctors and patients regarding the risks of Risperdal starting in 2002. Johnson & Johnson reported that it would appeal.
Shifting readers focus to broader market, let’s consider market performance of other stocks that significantly affect same sector. Pfizer Inc. (NYSE:PFE) increased +0.91% to settle at $22.14, GlaxoSmithKline plc (ADR) (NYSE:GSK) moved up +0.79% to end at $44.62 while Merck & Co., Inc. (NYSE:MRK) surged +0.34% to finish on Friday at $38.46.
Johnson & Johnson (NYSE:JNJ) last session volume of 11.25 million shares was slightly lower than its average volume of 12.13 million shares. The stock after opening at $62.54 hit high price of $63.04 and then closed at $62.98 by scoring +0.29%.
The liquidity measure in recent quarter results of the company was recorded 2.69 as current ratio and on the other side the debt to equity ratio was 0.32 and long-term debt to equity ratio also remained 0.21. The Company had total cash at hand $33.85 billion and a book value per share as $22.35 in the most recent quarter.
The stock price volatility was 1.05% for a week and 0.99% for a month as well as price volatility’s Average True Range for 14 days was 0.65 and its beta remained 0.54.
JNJ generated revenue of 65.00 billion in the following twelve months and earned $10.11 billion. The Company showed a negative 15.55% in the net profit margin and as well as in its operating margin which remained 19.84%. Company’s annual sales growth for the past five year was 4.05%.
DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! QuoteDaddy.com delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with QuoteDaddy.com! CLICK HERE TO START YOUR FREE 30-DAY TRIAL